Reimagining Medicine Q2 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
Submission enabling readouts expected to increase in
2024-2025 timeframe
Selected key assets* with submission enabling readouts in 2024-2025
Remibrutinib
CSU
Primary analysis¹ in H2 2023
Final (52 weeks) readout and
submission in 2024
ScemblixⓇ
1L CML-CP
Readout and submission in 2024
PluvictoⓇ
MHSPC
Readout and submission in 20242
OAV-101
SMA IT
Readout in 2024; submission in 2025
Pelacarsen
CVRR
Readout and submission in 2025
lanalumab
1L and 2L ITP readouts in 2025
with submission in 2026
Additional hematology and
immunology indications 2026+
Iptacopan
Additional readouts/submissions
in 2025/2026+
INNOVATION
*Unprobabilized peak sales of all asset indications in late-stage development:
> USD 1bn
> USD 2bn
> USD 3bn
CSU chronic spontaneous urticaria.
reduction. ITP
immune thrombocytopenia.
CML-CP - chronic myeloid leukemia in chronic phase. mHSPC metastatic hormone-sensitive prostate cancer.
1. Double blind treatment period of 24 weeks with primary analysis at 12 weeks. 2. Event-driven study endpoint.
SMA IT-spinal muscular atrophy intrathecal. CVRR-cardiovascular risk
16 Investor Relations | Q2 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation